SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (140)	5/4/2001 12:15:39 PM
From: Jim Oravetz	Read Replies (1) of 164

Oncolytics Files For Phase II Human Reolysin Trials Dow Jones Newswires CALGARY -- Oncolytics Biotech Inc. (T.ONC) has filed an investigational drug submission with Health Canada to start its first Phase II human clinical trial for Reolysin. In a news release, the company said Reolysin is the formulation of the reovirus which is a potential therapeutic for a broad range of cancers in humans. Oncolytics said it is proceeding with this study in order to demonstrate Reolysin's activity in solid tumors of a specific cancer type. It said "the study design will allow us to measure overall tumor response, and allow us to examine changes or effects inside the tumor." Oncolytics said it plans to proceed with up to three new clinical trial programs of Reolysin to examine the efficacy and safety of the product through various routes of administration in a number of cancer indications. Initial studies will examine discreet cancers where the product is best suited for direct tumor injection. Subsequent studies being planned will investigate the effectiveness of the product when delivered systemically, it noted. Oncolytics said it anticipates that these trials could run at the same time. Oncolytics Biotech Inc. (T.ONC) said that, subject to regulatory approvals, the Phase II clinical trial is intended to evaluate the efficacy of intra-tumoral administration of Reolysin for the treatment of Stage T2A prostate cancers. The study will initially include a dose ranging element to determine the minimum dose required to safely cause substantial tumor necrosis, or death, and will then enrol up to 30 patients at the appropriately determined dosage range. The trial is expected to be run in two centers and enrol a total of about 40 evaluable patients. Oncolytics said it is in the process of completing its Phase I human clinical trial of Reolysin. Oncolytics is a biotechnology company. Company Web Site: oncolyticsbiotech.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next